MAPC treatment of brain injuries and diseases

Patent metadata

Field	Value
Publication number	US-11351202-B2
Application number	US-201715849181-A
Country	US
Kind code	B2
Filing date	Dec 20, 2017
Priority date	Nov 9, 2005
Publication date	Jun 7, 2022
Grant date	Jun 7, 2022

Abstract

The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.

First claim

What is claimed is:

1. A method of ameliorating a brain injury caused by hypoxia in a human subject, comprising: administering to a human subject having a brain injury caused by hypoxia mammalian multipotent adult progenitor cells characterized in that: they are not embryonic stem cells, embryonic germ cells, or germ cells, are allogeneic to the subject, express telomerase, have a normal karyotype, and have undergone at least 10-40 cell doublings in culture, wherein the subject has an immune system and wherein further the subject is not treated with immunosuppressive therapy adjunctively to administration of said cells.

2. A method according to claim 1 , wherein said progenitor cells can differentiate into cells of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

3. A method according to claim 1 , wherein said progenitor cells are human cells.

4. A method according to claim 1 , wherein said progenitor cells are derived from cells isolated from any of placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, adipose tissue, and liver tissue.

5. A method according to claim 4 , wherein said progenitor cells are derived from bone marrow.

6. A method according to claim 5 , wherein said progenitor cells are derived from human bone marrow.

7. A method according to any one of claims 1 , 3 6 , wherein the brain injury is hypoxic ischemic brain injury.

8. A method according to any one of claims 1 , 3 6 , wherein the brain injury is caused by an occlusion or a blockage of blood supply.

9. A method according to any one of claims 1 , 3 6 , wherein the brain injury is a cortical infarction.

10. A method according to any one of claims 1 , 3 6 , wherein the brain injury is a stroke.

11. A method according to claim 1 , wherein said progenitor cells are administered to said subject in one or more doses comprising 10 5 to 10 8 of said cells per kilogram of the subject's mass.

12. A method according to claim 11 , wherein said progenitor cells are administered to the subject in one or more doses comprising 10 6 to 5×10 7 of said progenitor cells per kilogram of the subject's mass.

13. A method according to claim 1 , wherein in addition to said progenitor cells, one or more growth factors, differentiation factors, signaling factors, and/or factors that increase homing are administered to said subject.

14. A method according to claim 1 , wherein further any combination of one or more of each of the following is administered to said subject: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

15. A method according to claim 1 , wherein said progenitor cells are administered in a formulation comprising one or more other pharmaceutically active agents.

16. A method according to claim 15 , wherein said formulation further comprises any combination of one or more of: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

17. A method according to claim 1 , wherein said progenitor cells are administered to the subject by a parenteral route.

18. A method according to claim 17 , wherein said progenitor cells are administered by intravenous infusion.

19. A method according to claim 1 , wherein said progenitor cells are administered to the subject by stereotactic injection.

20. A method according to claim 2 , wherein said progenitor cells are derived from human bone marrow.

21. A method according to claim 20 , wherein the brain injury is hypoxic ischemic brain injury.

22. A method according to claim 20 , wherein the brain injury is caused by an occlusion or a blockage of the blood supply.

23. A method according to claim 20 , wherein the brain injury is a cortical infarction.

24. A method according to claim 20 , wherein the brain injury is a stroke.

Assignees

• Athersys Inc
• Univ Res Inst Inc Augusta
• Abt Holding Co

Inventors

• Mays Robert
• Deans Robert J
• Hess David C
• Carroll James E
• Borlongan Cesar V

Classifications

• A61K35/545 Primary

  Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title

• A61P17/06

  Antipsoriatics · CPC title

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title